|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.11.25 - 19:15
|
Singapore-based ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors; Announces Key Licensing Deal, New Board and SAB Appointments (Business Wire)
|
|
|
“Seed-and-Boost” Approach with Breakthrough Potential, Poised to Transform the Cancer Immunotherapy LandscapeSINGAPORE--(BUSINESS WIRE)--ImmunoScape Pte. Ltd., an A*STAR spin out backed by Amgen Ventures and EDBi that is developing next-generation TCR-based cancer immunotherapies, today announced an exclusive in-licensing deal with Cue Biopharma Inc. (Nasdaq: CUE) to lead the development of a distinct new class of therapies to attack solid tumor cancers. The deal provides ImmunoScape with exclusive access to Cue Biopharma's clinical-stage Immuno-STAT® molecules in oncology.
By combining Cue Biopharma's technology with its precision T cell receptor (TCR) therapy, ImmunoScape is pioneering a new “Seed-and-Boost” approach to immunotherapy, that addresses the shortcomings of current cell therapies by enabling potent in vivo expansion of infused tumor targeting T-cells—producing large numbers of highly effective tumor killing T cells in a controlled manner in the patient.
The strategy uses a minim...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.11.25 - 15:31
|
Opening Bell: Wall Street startet im Plus; Alphabet, Snap, Solaredge, Robinhood, Amgen, Axon Enterprise, Marvell Technology im Fokus (Der Aktionaer)
|
|
|
An den US-Aktienmärkten sieht es am Donnerstag nach einem verhalten positiven Auftakt aus. Am Markt hieß es, die am Vortag aufgekommene Bereitschaft, den Kursrückgang vom Dienstag zum Zukauf zu nutzen, sei in Maßen immer noch spürbar. Während die laufende Berichtssaison die Stimmung weiter nicht eindeutig prägen kann, werden die hohen Bewertungen von Technologieaktien weiter hinterfragt....
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
